Editas Medicine, Inc. (EDIT)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Editas Medicine, Inc. reported revenue of $40.52M, up 25.4% from the prior year. The company ran a net loss, with a net margin of -395.0%. It held $186.53M in total assets against $159.25M in total liabilities.
Key ratios (FY2025)
-394.9%
Operating margin
-395.0%
Net margin
-586.6%
Return on equity
+25.4%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $40.52M | $32.31M | $78.12M | $19.71M | $25.54M | $90.73M | $20.53M | $31.94M | $13.73M | — |
| Operating Income | -$160.01M | -$251.15M | -$169.18M | -$225.95M | -$193.15M | -$134.84M | -$140.92M | -$113.73M | -$119.93M | -$97.19M |
| Net Income | -$160.06M | -$237.09M | -$153.22M | -$220.43M | -$192.50M | -$115.98M | -$133.75M | -$109.95M | -$120.32M | -$97.18M |
| EPS (Diluted) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.68 | — | — | — |
| Total Assets | $186.53M | $341.59M | $499.15M | $514.32M | $677.48M | $572.60M | $508.88M | $420.39M | $373.26M | $229.18M |
| Total Liabilities | $159.25M | $207.31M | $150.06M | $153.64M | $123.84M | $179.02M | $246.45M | $184.22M | $165.18M | $94.58M |
| Shareholders' Equity | $27.29M | $134.27M | $349.10M | $360.68M | $553.64M | $393.59M | $262.44M | $236.16M | $208.08M | $134.61M |
| Cash & Equivalents | $146.65M | $131.54M | $123.65M | $141.52M | $203.52M | $139.68M | $238.18M | $134.78M | $146.63M | $185.32M |
| Operating Cash Flow | -$165.24M | -$210.28M | -$132.18M | -$177.35M | -$163.80M | -$179.84M | -$40.67M | -$45.71M | -$9.42M | -$50.25M |
| Capital Expenditures | $607.0K | $8.83M | $4.72M | $4.12M | $7.98M | $7.16M | $6.17M | $4.75M | $2.06M | $3.49M |
| Shares Outstanding | 97.87M | 82.73M | 81.77M | 68.85M | 68.44M | 62.56M | 54.36M | 48.76M | 44.51M | 35.82M |